Supernus Pharmaceuticals
SUPN
230 hedge funds and large institutions have $1.64B invested in Supernus Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 101 reducing their positions, and 33 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
34% more call options, than puts
Call options by funds: $5.37M | Put options by funds: $4M
3% more capital invested
Capital invested by funds: $1.59B → $1.64B (+$52.8M)
3% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 33
2% less funds holding
Funds holding: 235 → 230 (-5)
2.66% less ownership
Funds ownership: 103.85% → 101.19% (-2.7%)
33% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 101
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$14.9M |
| 2 |
BlackRock
New York
|
+$13.4M |
| 3 |
Goldman Sachs
New York
|
+$8.76M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.7M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$7.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$31.8M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$8.18M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$7.43M |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$6.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.48M |
SUPN Hedge Fund Activity: Q1 2022 in Review
230 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2022, worth a combined $1.64B — up 3.3% from $1.59B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of SUPN and 32 opened new positions — a net loss of 1 holder — while 101 trimmed existing stakes and 68 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $14.9M. The largest seller was Armistice Capital, cutting an estimated $31.8M.
- 230 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2022, down from 235 in Q4 2021.
- Funds reported $1.64B of Supernus Pharmaceuticals stock for Q1 2022, up 3.3% quarter-over-quarter.
- 32 funds opened new Supernus Pharmaceuticals positions in Q1 2022 and 33 closed out, a net change of -1 holder.
- The largest Supernus Pharmaceuticals buyer in Q1 2022 was Woodline Partners, an estimated $14.9M added.
- The largest Supernus Pharmaceuticals seller in Q1 2022 was Armistice Capital, an estimated $31.8M sold.
Based on aggregated 13F filings for Q1 2022.